Novavax, Inc. reports results for the quarter ended June 30 - Earnings Summary

Novavax

06/08/2026 15:07

Novavax, Inc. NVAX.OQ reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 62 cents.  The mean expectation of eight analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -50 cents to -25 cents per share.
Revenue fell 76.3% to $56.70 million from a year ago; analysts expected $52.51 million. 
Novavax, Inc.'s reported EPS for the quarter was a loss of 32 cents​.
The company reported a quarterly loss of $53.39 million.
Novavax, Inc. shares had fallen by 18.3% this quarter and gained 14.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 7% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and 3 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Novavax, Inc. is $16.00, about 51.9% above its last closing price of $7.70
This summary was machine generated from LSEG data August 6 at 02:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.39
-0.32
Beat
Mar. 31 2026 
-0.23
-0.06
Beat
Dec. 31 2025 
-0.49
0.11
Beat
Sep. 30 2025 
-1.19
-1.25
Missed